XIANGYANG LI: Open Payments
NPI 1497719132 · MILFORD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,374 in 185 payments from 18 companies in 2025. Trend: 2023 $43,920 · 2024 $19,356 · 2025 $3,374
Food & beverage: $3,255Education: $119
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 32 | $498 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $472 |
| Alkermes, Inc. | 23 | $421 |
| Axsome Therapeutics, Inc. | 16 | $331 |
| Janssen Pharmaceuticals, Inc | 13 | $284 |
| Otsuka America Pharmaceutical, Inc. | 12 | $246 |
| Lundbeck LLC | 10 | $230 |
| Neurocrine BioSciences, Inc. | 12 | $195 |
| ABBVIE INC. | 12 | $186 |
| Teva Pharmaceuticals USA, Inc. | 8 | $171 |
Products named: FANAPT, REXULTI, CAPLYTA, ARISTADA, INGREZZA, VRAYLAR, Auvelity, VIVITROL.
Industry payments across MA — which companies pay providers there.
